title: 131I effective half-life and dosimetry in thyroid cancer patients.
abstract: (131)I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer and leukemia. There are still some uncertainties concerning parameters that may influence the effective half-life of (131)I and the absorbed doses by extrathyroidal organs.
  
  
  METHODS
  Whole-body retention of radioiodine was measured in 254 patients, and repeated quantitative whole-body scans and measurements of the urinary excretion of (131)I were performed on 30 of these patients.
  
  
  RESULTS
  The mean effective half-life (10.5 h) was shorter by 31%, with little difference between patients, in the 36 patients who received recombinant human thyroid-stimulating hormone than in the 218 patients who underwent thyroid hormone withdrawal (15.7 h). The residence times in the stomach and in the rest of the body were significantly shorter in patients who received recombinant human thyroid-stimulating hormone than in patients who underwent withdrawal, but the residence times were similar in the colon and bladder.
  
  
  CONCLUSIONS
  In patients who undergo thyroid hormone withdrawal, the longer mean effective half-life is mainly due to delayed renal excretion of (131)I and results in dose estimates higher than the data in report 53 of the International Commission on Radiological Protection, which were obtained from healthy, euthyroid subjects.
authors.affiliation: Department of Nuclear Medicine, Institut Gustave Roussy, Villejuif, France. herve.remy@igr.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Remy
authors.forename: Isabelle
authors.initials: I
authors.lastname: Borget
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: Nadine
authors.initials: N
authors.lastname: Guilabert
authors.forename: Frédéric
authors.initials: F
authors.lastname: Lavielle
authors.forename: Jérome
authors.initials: J
authors.lastname: Garsi
authors.forename: Claire
authors.initials: C
authors.lastname: Bournaud
authors.forename: Séverine
authors.initials: S
authors.lastname: Gupta
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.forename: Marcel
authors.initials: M
authors.lastname: Ricard
mesh_terms: D000328:Adult; D001822:Body Burden; D005260:Female; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D012062:Relative Biological Effectiveness; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D014915:Whole-Body Counting / Q000379:methods*
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals